385 related articles for article (PubMed ID: 28938888)
1. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
[TBL] [Abstract][Full Text] [Related]
3. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
4. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.
Wibmer CK; Gorman J; Anthony CS; Mkhize NN; Druz A; York T; Schmidt SD; Labuschagne P; Louder MK; Bailer RT; Abdool Karim SS; Mascola JR; Williamson C; Moore PL; Kwong PD; Morris L
J Virol; 2016 Nov; 90(22):10220-10235. PubMed ID: 27581986
[TBL] [Abstract][Full Text] [Related]
5. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
Pinter A; Honnen WJ; Racho ME; Tilley SA
AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
[TBL] [Abstract][Full Text] [Related]
6. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
[TBL] [Abstract][Full Text] [Related]
7. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice.
Galkin A; Chen Y; Guenaga J; O'Dell S; Acevedo R; Steinhardt JJ; Wang Y; Wilson R; Chiang CI; Doria-Rose N; Grishaev AV; Mascola JR; Li Y
J Immunol; 2020 Mar; 204(6):1543-1561. PubMed ID: 32066595
[TBL] [Abstract][Full Text] [Related]
9. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
10. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
[TBL] [Abstract][Full Text] [Related]
11. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
[TBL] [Abstract][Full Text] [Related]
12. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
[TBL] [Abstract][Full Text] [Related]
13. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
Tolbert WD; Nguyen DN; Tehrani ZR; Sajadi MM; Pazgier M
mBio; 2021 Aug; 12(4):e0127421. PubMed ID: 34281393
[TBL] [Abstract][Full Text] [Related]
14. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site.
Vijh-Warrier S; Pinter A; Honnen WJ; Tilley SA
J Virol; 1996 Jul; 70(7):4466-73. PubMed ID: 8676471
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
Matsushita S; Matsumi S; Yoshimura K; Morikita T; Murakami T; Takatsuki K
J Virol; 1995 Jun; 69(6):3333-40. PubMed ID: 7538171
[TBL] [Abstract][Full Text] [Related]
16. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
Front Immunol; 2021; 12():670561. PubMed ID: 35003053
[TBL] [Abstract][Full Text] [Related]
17. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
[TBL] [Abstract][Full Text] [Related]
18. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120.
Bagley J; Dillon PJ; Rosen C; Robinson J; Sodroski J; Marasco WA
Mol Immunol; 1994 Oct; 31(15):1149-60. PubMed ID: 7935503
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.
Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG
J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181
[TBL] [Abstract][Full Text] [Related]
20. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
